Invion Stock

Invion Accounts Payable

Accounts Payable of Invion (IVX.AX) as of Sep 12, 2026.

Accounts Payable

0.00AUD

Last updated:

Accounts Payable of Invion is 2026 0.00 AUD. Accounts Payable of Invion was 2025 0.00 AUD. It decreases by % lower compared to the previous year.

The Invion Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2016
466,600.00 AUD
Jan 1, 2017
492,600.00 AUD
Jan 1, 2018
782,100.00 AUD
Jan 1, 2019
308,100.00 AUD
Jan 1, 2020
105,700.00 AUD
Jan 1, 2021
448,900.00 AUD
Jan 1, 2022
221,300.00 AUD
Jan 1, 2023
400,000.00 AUD
The Invion Accounts Payable history
YEARAccounts PayableYoY
400,000.00AUD+80.75%
221,300.00AUD-50.70%
448,900.00AUD+324.69%
105,700.00AUD-65.69%
308,100.00AUD-60.61%
782,100.00AUD+58.77%
492,600.00AUD+5.57%
466,600.00AUD-72.64%
1.71 MAUD+154.95%
668,800.00AUD+42.30%
470,000.00AUD+23.68%
380,000.00AUD-51.90%
790,000.00AUD-29.46%
1.12 MAUD-75.44%
4.56 MAUD+31.79%
3.46 MAUD+86.02%
1.86 MAUD+72.22%
1.08 MAUD—
Access this data via the Eulerpool API
Get Free API Key

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

On Eulerpool you can find the complete historical development of Accounts Payable Invion since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Invion historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Invion

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Invion